In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

And other biotech news brought to you by The Readout.

NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday issued two final guidances, in which it recommended against making Eisai and Biogen's Leqembi (lecanemab) and Eli ...

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

And more pharma news updates from Pharmalittle.

Jim Rogers, 58, was living and working in Australia when he started to develop symptoms of the incurable neurological ...

Microsoft co-founder Bill Gates reflects on his father's Alzheimer's battle and expresses optimism about advancements in ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

The re-examination of donanemab, marketed as Kisunla, began on June 2 following a request from Eli Lilly, according to the committee’s monthly meeting highlights on Friday. The committee had ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

NICE decided that two Alzheimer’s drugs are too expensive for their modest benefits and cannot be recommended for NHS use in ...